Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You Is Abbott's January Pullback a Good Time to Buy? Author: Thomas Hughes. First Published: 1/24/2026. 
At a Glance - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories (NYSE: ABT)'s January 2026 price pullback has made the stock look attractively valued. The move — driven more by market angst than by underlying company weakness — appears to be a knee-jerk overreaction that has pushed the shares back into a buy zone. 
Many investors focus on identifying the next breakout AI stock. Others are taking a different approach — looking at the infrastructure that AI companies rely on regardless of which names lead the sector.
In a recent briefing, one analyst outlines how certain income-focused investments tied to AI infrastructure may generate recurring cash flow across different market conditions, without requiring investors to predict individual winners. See the AI infrastructure income ideas here The zone in question aligns with price action from 2022 to 2024, when Abbott was recovering from a post-COVID-19 revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates The most that can be said against Abbott Laboratories' Q4 results and guidance is that a few metrics missed market expectations. Still, revenue of $11.46 billion was up 4.5% year-over-year, margins improved, and adjusted earnings accelerated. Revenue growth missed by several hundred basis points, but margin strength helped offset that shortfall. Adjusted earnings per share (EPS) rose 12%, coming in slightly above consensus. Segment results highlighted the benefits of Abbott's diversified healthcare portfolio. The Nutrition and Diagnostics segments contracted — Nutrition fell nearly 9% — but those declines were offset by solid growth in Established Pharmaceuticals and Med Tech. The Established Pharmaceuticals segment grew about 9%, driven by generics and emerging markets, while Med Tech rose 12.3%, showing strength across its subsegments. Margins were a bright spot. A favorable product mix, strength in Med Tech, lower COVID-19 sales and operational improvements left margins ahead of forecasts. Looking ahead, the company expects this trend to continue, forecasting roughly 10% earnings growth in 2026 — outpacing revenue growth and supporting its capital-return plans. Abbott's capital returns are a key part of the investment case. The company is a Dividend King, having raised its payout annually for more than 50 years, and appears positioned to continue that streak. After the pullback the stock yields roughly 2.5%, and Abbott's payout ratio is below 50% of consensus EPS, leaving cash flow available for share buybacks, which help offset dilutive share-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts flagged the revenue miss, but no major rating or price-target changes were issued the morning of the release. The prevailing view remains that this fundamentally healthy company can continue returning capital while reinvesting in growth, and the longer-term growth outlook is meaningful. The consensus share price target reported by MarketBeat implies the stock could rebound as much as 30%, potentially reaching new all-time highs, while even the low-end targets imply some upside. Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, margin expansion and strategic acquisitions. The proposed acquisition of Exact Sciences, for example, would broaden revenue and profit streams as well as the product pipeline. That said, the recent decline has been steep and could deepen. Institutions, however, were net buyers throughout 2025 and are likely to add at discounted prices. Early technical support appears in the $105 to $110 range, though it is not yet confirmed. The risk remains that ABT shares could slide to the low end of the target buy zone before rebounding — potentially testing the $95 level or lower.
| 
